If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
While there it is known that progestogens reduce spontaneous preterm birth in women with a mid-trimester short cervix, studies on cervical pessary show conflicting results. We compared the additional effectiveness of cervical pessary for the prevention of preterm birth in women with a mid-trimester short cervix already using progesterone.
We performed a multicenter randomized controlled trial in 18 perinatal centers in Brazil (RBR-3t8prz UTN:U1111-1164-2636). Asymptomatic women with a singleton or twin pregnancy and a CL ≤ 30mm, measured at 16+0 – 22+6 weeks gestation, were randomized to cervical pessary + vaginal progesterone or vaginal progesterone (200mg daily) alone. Treatments were used from randomization to 36 weeks of gestation or delivery. The primary outcome was a composite of neonatal mortality and morbidity. Secondary outcomes were among others delivery <37 weeks and delivery <34 weeks. We planned subgroup analysis according to cervical length (≤ 25 mm), parity and the number of fetuses (singletons or twins).
Between July 15, 2015 and March 29, 2019, we measured cervical length in 8,490 women, of which 475 women were randomized to receive pessary + progesterone and 461 women to progesterone alone. The primary composite perinatal outcome occurred in 89/463 19.2% versus (91/436) 20.9%, respectively (RR 0·85, 95% CI 0·55 to 1·1). Delivery rates < 37 weeks were 29·1% versus 31·4% (RR 0·86 CI 0·72 - 1·04) while < 34 weeks, delivery rates were 9·9% versus 13·9% (RR 0·66 CI 0·47-0·93). In women with a nulliparous singleton pregnancy and cervical length ≤ 25 mm, the composite perinatal outcomes occurred in 20% versus 33% of the women (RR 0.59, 95% CI 0.37 – 0.94, p-value 0.02).